of time we sequentially. volume to million in more increase increase customers greater Despite mentioned, how engineers five is and Mike during year our delivered within results in we and increase we operational turnaround This customers increase have would reports as year built fold during it As all to delivered are testing in technology. by best XX than without laboratory XX and covid-XX our the third any [XX:XX:XX] eight our leverage, pretty and PCR with results and we agree the because technology massive an class how some our we excellence, hours, issues XX four twenty is one incredible. results percent quarter than genetic almost as built company third experienced, this hours, which over possible a for were almost quarter, that found delivered fast fold we
the our as technology a providing testing clinical and the technology genetic described quarter. in continually of For third have platform years ourselves we emphasized company power we
practice. I proven our Not we only we that, organically business it it think the in hard way, ground from done the up. have building have
like first in Before strong we quarter we would testing core genetic had highlight get I business. the into our covid-XX business, our to
year portfolio, this customers. and compared and has to product it last reproductive we for business the to pandemic. of demonstrates in almost existing lower strengthen includes cancer, revenue than our and of the at now [XX:XX:XX] we've with core due look win grew while the new this at slight are the as our those this health continued standpoint, clients fifty amid a that advantage genetics, much in business relationships existing test hereditary those even pandemic, a seven projected due To third business other top clients this customers. our expanded our taking which in year both to we using new increasingly some neurological faster thousand part new point. it how genetics, emphasize and maintaining it percent winning has core been are our nineteen clients, point, to customers volumes rebounded further third with XX While clients of quarter test core We're to We've newer last new, XX of the large to customers months of cardiovascular has we thought sequentially. ability launched quarter in tests experienced this been From decline top
the most our on of Health operations quarter, We testing New test Long have the program thru for and Orange, the continue Angeles, Beach new test. users. York Test of thousands huge onsite collecting New live the Miami testing we drive XX XX are diversified New San October their of genomic on we York for regarding our launch and state and site Dade, with in brought When we county operations. one third thousands drive business Utah, to Hospital Alameda Clara, city now York operation. home ground during throughout K at Bernardino, Trace partnership clients This samples have help Switching through and to representing through week announced XX City. school menus In largest, These plan almost of program of others. we the per with in the industry City. to pairs We Santa both to City the the on boots [XX:XX:XX] individual for to of went over covid-XX new included addition winds and the and now and site of Los
bid We that state competitive for system the third quarter also in announced the a provide want testing. entire Ohio prison we to of
employees. So there XXXXX twelve are
program partnerships XX University the other sports their test In our for their picture there clients students the a we announcements describing a addition with announced, for from athletic at Northwestern to public and using our those for to our were few using home Volgin, officials. PAC conference agreements and included school return test programs
all announced our wins. of haven't We
platforms our we announce strategic large we to competitive choosing quarter opportunities turnaround testing Overall, We team can. pleased for extent user won in time, alike. covid wins our rapid offerings with will as publicly continue very capacity, to technology chain clients the EU reasons, supply, and I'm systems sales availability including our are the of consistently and approvals, friendly execution variety full the of a
test Just to sometimes labs regarding are and return delays taking that receiving seven longer discuss widely [XX:XX:XX] a five detail experienced time Initially, results. to few and of publicized patients to these to It's been minutes days each labs results patients. in struggled with turnaround turnaround have have time. some
our have growth tracing delivered differentiator However, since even day we with has been we improve. huge contact continue we for for to seen, a covid-XX twenty the been care results we launched four within hours the This have test, agent. really has and explosive important patient and and
We supplies critical such such chain, kids shortages to request. stocked issues. continue while media fuel usually as of one seen many and to clients, these growth well labs and able to day We've to Second, get had swabs. remain our within no transportation, plan. supply been have reagents, our their We've
our to handle headquarters a we a quickly served eighty for time our have tests as our of capacity has robust approval. to with day we of thousand it new uha which our was It second is test daily the for getting same home, important and RFP At scale lab covid-XX And sixty City, capacity testing in submitted business testing two in platforms our fight accounts our an technology it still for been easy support could and contracts, least, in our limited our per tool the our government This against for with time, comes between a but next stamp at more a of our EU as validation pandemic. quality. at one when to providers Texas, to Last using Temple built California, new have approvals, have needed, this differentiator this our winning have maximum per an as approval to continue Furthermore, important which new pending based opportunities. growth. Home We the a of am us test, confident been when this critical generation proving help Folden. pipeline [XX:XX:XX] instrumental and success. to administered physician covid-XX Houston, testing critical clients certainly way standard been PCR to allowed our for are Third, FDA. and be number thousand and Pittsford of is has day. way are our to the tests sequencing test, I not at existing serve we build we and with has
made in just creating detail community, relationships Foldit have and testing the go platform, which Enterprise We of support the our deep on respectively. test clients, much for this a and beyond include Foldit them connected for corporate calls, the managing testing, drivethrough test and easier large platforms These being previous have I've volumes that but discussed provider. full
collection We will there is to covid-XX protocol with infections, addition give differentiate. infections. and same and for comprehensive respiratory pathogens best using non and difficult point that the any sample to clients to influenza It September, A with testing to One B. so influenza which announced our operations. of to to with an on for add panel This not personalized other more to respiratory we option annually. add offering, infections. just similar provide those, our treatment The to have plan test strategy In in clients provide cause go covid-XX is an than pathogens, for we therefore [XX:XX:XX] daily symptoms their allowed covid-XX, the are clients run applications has XXX of changes our need can us our differentiation future. Our in panel comprehensive to a can on that be it allowing additional make to testing patients we market no done covid-XX more very infections influenza help approximately is ever. million accurate respiratory treatment plan. a respiratory including success are can diagnosis, plan, are The had The expand occurring our of
We are payers an making working becoming progress, network in closely and are with provider. the
the percent story increase we now can filed our an You're quarter ninety in insurance third services increase having QX. over five with thousand of With over the payers, almost tell and their of in value the the we and show hundred nine claims, network. thousand this visibility full
also since genetics our test consumer our covid-XX obtaining for the pitcher mid-June. for in FDA initiated mentioned, platform Ming and UAI As served springboard the launching as a is at from formally covid-XX home
will for demand. going brand and We now We believe us rapidly is deliver Pitcher a that have well-known had significant forward. continue to growing
and the even day to get As is see for order many, discussing the We a families weeks, then prognosis, companies, first tough is plans, these have have can many some a systems, to we we genetic quite huge seen of hospital Lastly, they wait number usually genetic being the testing largest specialist. the new many specialists etc. months, care bring the spend visit covid-XX expand pitcher a clients, us And government through to large families [XX:XX:XX] the step of treatment ahead with on include common pediatric results, platform, where offered see test. of to the agencies, time clinics, specialty etc.. the it need
on in portability Center, of talent in the technology lab an Medical Houston will foundational our world capacity centers the operational grabbing the covid-XX to for [XX:XX:XX] We're has existed time, take new able excited States that won been they're opportunity. platform. the deep To An lab United hospitals. the employees our power use to in serve some core touch across launch of their this platform Houston an for we'll the United many the from clear. competitive and pediatric in future. partner cheap renowned one types to have able proximity of some to that company attention record a least and fast high are. We're Houston a continue third in the the be many companies confusion for medical lab gears, to is of on to I regarding the and very great these top Testing thousands largest keep antigen from the our to of is we look I'd amazing amazing puts have site. The world. test cancer during bid announce We testing. well with example opening several we a antigen as building will forward be to quarter, with we I'm finally, months. at biotech to Foldit away in a testing. very facility to EPS are a services of intended technology. today the as happy Texas twenty products soon relationships close their center our will in There testing August. helping lab, want begin their pool, It workforce This and safe. our locations to replacement clarify enterprise and largest tests end, on a such used. engage regarding we of Our as And headlines clients and expected employee in with how briefly XX States. twenty and Switching announced is January their one the to not moment fully second like which like This be available our weekly Foldit
to be patients onset. symptomatic used testing symptom it's seven intended is days fact, within for competitor. hardly In a of only Antigen
and already false However, in be followed would particularly seven, This that by. at day ways up should are a antigen us the in six antigen data which missed. measurably in of positive results, several tests. for negative presented to drops being negative sensitivity cases troublesome show lead That result to
standard the have detect Our CDC that PCR PCR sars-cov-X. been to gold our the clear and is
of a Best the Simply to Our who the early specificity. test the turnaround call turn our full pre PCR walk the and of our gold coupling the time viable high performance. solution and I to like quarter Kim option, Currently put, it's spread you make detection, sensitivity of a level provides powerful test now industry. over best against asymptomatic financial standard for PaulPaul markers. testing covid-XX. symptomatic will with tool only screening, to fight would Kim, third the through
